On this week's episode of Lifehacker, we're diving into careers. We'll walk through how to ask for a raise you may actually get, start freelancing without quitting your day job, get hired when you don't have prior experience, and more.
This is the eight episode of season two of Lifehacker. Today's episode highlights:
Today's downloads include:
Hungry for a little more? Check out all the episodes in our summer series or the entire first season of Lifehacker.
Grab it in any format you like: If you don't want to watch it in your browser right now, you can catch the show wherever you want, and in nearly whatever format you like. Visit the episode page on Revision3 to download HD or phone-friendly versions of the show in MP4 or WMV. You can also subscribe in iTunes or via RSS, watch it on YouTube and subscribe to our channel there.
Update to iOS 5, Get a Raise, Start Freelancing, and Create a Business Plan | Revision3
You can contact Adam Pash, the author of this post, on Twitter, Google+, and Facebook.
Paramount Staffing ? Atlanta, GA ? Midtown Law Firm is seeking a Hospitality Assistant with 1+yrs of prior catering experience! Position includes coordinating the preparation, set up and break down of internal meetings and catered events! Must have the ability to read, analyze and interpret general business documentation? to or fax your resume to 404-760-4825. Keywords: legal, legal secretary, paralegal, legal office support, in-house legal positions, legal receptionist, legal clerk, legal assistant, assistant, legal secretary, legal hospitality assistant, hospitality assistant, legal hospitality, hospitality, catering ? Temporary ? Full-time
TRIPOLI (Reuters) ? Two bulldozers guarded by armed men started to demolish the walls around ousted leader Muammar Gaddafi's former home in the Libyan capital Tripoli Sunday.
As the bulldozers set to on the Bab al-Azizyah compound, men chanted, "God is greatest. This is for the blood of the martyrs." Some fired machine guns into the air.
"We are destroying it because we want to demolish anything that belongs to Gaddafi," one gunman, Essam Sarag, told Reuters.
People driving past stopped their cars and joined a crowd waving new Libyan flags.
"We will continue until we destroy everything that belongs to Gaddafi," said Etman Lelktah, who said he was in charge of the fighters at the scene.
"We ask that a peace organization be built instead of Gaddafi's place."
The heavily fortified compound, six sq-km (2.3 sq mi), was both the seat of Gaddafi's power and his Tripoli home.
It was targeted by NATO warplanes several times before Tripoli fell to the now ruling National Transitional Council in August.
(Writing by Barry Malone; Editing by Angus MacSwan)
Jon Jones defending his title for a second time, against Lyoto Machida is a must watch in early December, but that means we once again have to wait for Jones vs. Rashad Evans. Some in the media believe booking Jones-Machida was a big mistake. Was it?
Larry Pepe from ProMMARadio.com checked in with us to express his concerns about shelving Jones-Evans.
The UFC held an early UFC 140 prefight press conference in Toronto on Wednesday, the staredown between Jones and Machida looked pretty intense.
Drug safety, efficacy, and potential new cancer biomarker predicted by NextBioPublic release date: 14-Oct-2011 [ | E-mail | Share ]
Contact: Joan Kureczka Joan@kureczka-martin.com 415-821-2413 Kureczka/Martin Associates
NextBio's unique capabilities for life science discovery and clinical insights from genomic data highlighted at ASHG/ICHG Meeting
SANTA CLARA, CA (October 14, 2011): New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation. The unique capabilities of NextBio to search and make discoveries, not possible by other methods, from the massive amounts of genomic data increasingly available in the public domain is the subject of two poster presentations at the American Society of Human Genetics/International Congress of Human Genetics meeting in Montreal, October 11-15.
In one presentation, the authors showed how NextBio's web-based tools and integrative genomics data could be used to evaluate potential drug toxicities and suggest treatment alternatives for women experiencing "hot flashes" (vasomotor symptoms) as a result of breast cancer chemotherapy. In another presentation, NextBio authors demonstrated how genomic data from disparate sources could be brought together and analyzed on the NextBio platform to suggest a potential new cancer biomarker in a region of the genome previously termed a "gene desert."
Drug Toxicity, Alternative Therapy Identified by NextBio
NextBio analysis offers the potential to inform clinical medicine through its ability to predict drug toxicities, as illustrated by a study of tibolone, a drug widely used to treat menopausal vasomotor symptoms. In 2009, a clinical trial tested this drug as a potential therapy for similar symptoms in women undergoing breast cancer treatment. The trial was cut short early because of the significant increase in cancer recurrence observed in those women.
The authors' investigation of public genomic data curated by NextBio found positive correlations between tibolone-induced gene expression changes and those seen in breast cancer, as well as similarities to the gene expression profiles of estradiol hormone replacement therapy (HRT), which is contraindicated in patients with breast cancer. A similar analysis for gabapentin, another drug used to treat vasomotor symptoms, showed gene expression changes that are not correlated with breast cancer, HRT, or tibolone signatures, suggesting that gabapentin may offer a better alternative to tibolone for patients with breast cancer.
"Together, these and other analyses performed as part of this study demonstrate that NextBio's web-based tools and integrative genomics data can aid applications such as assessment of potential drug efficacy or adverse effects," said Helen Wang, NextBio scientist and lead author of the study.
Identification of Potential New Cancer Biomarker
A second study presented by NextBio showed how using genomic data curated from publicly available sources; researchers could perform in silico analysis to identify a possible new cancer biomarker in a portion of the genome previously known as a "gene desert".
Cellular changes involved in cancer are not unlike those involved in creating stem cells from adult tissues like skin. In both cases, cells re-gain the ability to multiply rapidly, and lose certain characteristics of adult, differentiated tissues. Analyzing data integrated from studies of genomic changes in stem cells with studies of several cancer types, the group identified a poorly characterized gene that was highly up-regulated in both cancer cells and stem cells, but not normal mature or otherwise differentiated cells.
"NextBio offers an unprecedented opportunity for life scientists to find correlations and make new findings from the rapidly rising mountains of publicly available genomic data, as well as from their own research results," said Ilya Kupershmidt, NextBio vice president of products. "As we enter the era of the $1000 genome, the NextBio platform can provide an important resource for analyzing and understanding genomic data from disparate sources, leading to new knowledge and the potential for better decision making for life science researchers, drug developers, and clinicians alike."
###
About NextBio
NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio's unique 'correlation engine' pre-computes billions of significant connections among public and private data and enables researchers to intelligently mine and interpret it in real-time. In doing so, it helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers at the world's top commercial and academic institutions. NextBio's Enterprise solution has been deployed at the University of Southern California, Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, UCB, and Takeda, among many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.
Contacts:
Saeid Akhtari
President and CEO
NextBio
saeid@nextbio.com
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Drug safety, efficacy, and potential new cancer biomarker predicted by NextBioPublic release date: 14-Oct-2011 [ | E-mail | Share ]
Contact: Joan Kureczka Joan@kureczka-martin.com 415-821-2413 Kureczka/Martin Associates
NextBio's unique capabilities for life science discovery and clinical insights from genomic data highlighted at ASHG/ICHG Meeting
SANTA CLARA, CA (October 14, 2011): New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation. The unique capabilities of NextBio to search and make discoveries, not possible by other methods, from the massive amounts of genomic data increasingly available in the public domain is the subject of two poster presentations at the American Society of Human Genetics/International Congress of Human Genetics meeting in Montreal, October 11-15.
In one presentation, the authors showed how NextBio's web-based tools and integrative genomics data could be used to evaluate potential drug toxicities and suggest treatment alternatives for women experiencing "hot flashes" (vasomotor symptoms) as a result of breast cancer chemotherapy. In another presentation, NextBio authors demonstrated how genomic data from disparate sources could be brought together and analyzed on the NextBio platform to suggest a potential new cancer biomarker in a region of the genome previously termed a "gene desert."
Drug Toxicity, Alternative Therapy Identified by NextBio
NextBio analysis offers the potential to inform clinical medicine through its ability to predict drug toxicities, as illustrated by a study of tibolone, a drug widely used to treat menopausal vasomotor symptoms. In 2009, a clinical trial tested this drug as a potential therapy for similar symptoms in women undergoing breast cancer treatment. The trial was cut short early because of the significant increase in cancer recurrence observed in those women.
The authors' investigation of public genomic data curated by NextBio found positive correlations between tibolone-induced gene expression changes and those seen in breast cancer, as well as similarities to the gene expression profiles of estradiol hormone replacement therapy (HRT), which is contraindicated in patients with breast cancer. A similar analysis for gabapentin, another drug used to treat vasomotor symptoms, showed gene expression changes that are not correlated with breast cancer, HRT, or tibolone signatures, suggesting that gabapentin may offer a better alternative to tibolone for patients with breast cancer.
"Together, these and other analyses performed as part of this study demonstrate that NextBio's web-based tools and integrative genomics data can aid applications such as assessment of potential drug efficacy or adverse effects," said Helen Wang, NextBio scientist and lead author of the study.
Identification of Potential New Cancer Biomarker
A second study presented by NextBio showed how using genomic data curated from publicly available sources; researchers could perform in silico analysis to identify a possible new cancer biomarker in a portion of the genome previously known as a "gene desert".
Cellular changes involved in cancer are not unlike those involved in creating stem cells from adult tissues like skin. In both cases, cells re-gain the ability to multiply rapidly, and lose certain characteristics of adult, differentiated tissues. Analyzing data integrated from studies of genomic changes in stem cells with studies of several cancer types, the group identified a poorly characterized gene that was highly up-regulated in both cancer cells and stem cells, but not normal mature or otherwise differentiated cells.
"NextBio offers an unprecedented opportunity for life scientists to find correlations and make new findings from the rapidly rising mountains of publicly available genomic data, as well as from their own research results," said Ilya Kupershmidt, NextBio vice president of products. "As we enter the era of the $1000 genome, the NextBio platform can provide an important resource for analyzing and understanding genomic data from disparate sources, leading to new knowledge and the potential for better decision making for life science researchers, drug developers, and clinicians alike."
###
About NextBio
NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio's unique 'correlation engine' pre-computes billions of significant connections among public and private data and enables researchers to intelligently mine and interpret it in real-time. In doing so, it helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers at the world's top commercial and academic institutions. NextBio's Enterprise solution has been deployed at the University of Southern California, Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, UCB, and Takeda, among many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.
Contacts:
Saeid Akhtari
President and CEO
NextBio
saeid@nextbio.com
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
McLEAN, Va. ? The United States accused Syrian President Bashar Assad's government of using an American citizen to spy on anti-Syrian protesters in the U.S., further straining relations with Damascus over a brutal crackdown on dissidents that has killed thousands.
Mohamad Anas Haitham Soueid, 47, of Leesburg, a Syrian-born, naturalized U.S. citizen, is accused of sending audio and video recordings of American protesters to Syria's intelligence agency and traveling to Syria to meet directly with Assad.
The Syrian embassy issued a statement strongly denying that Soueid was an agent for them or that he personally met with Assad. It called the accusation "absolutely baseless and totally unacceptable."
International pressure is building on Assad to step down over his regime's bloody crackdown on anti-government protests that the U.N. says has left nearly 3,000 people dead. Earlier Wednesday, tens of thousands of Syrians gathered in Damascus to show their support for Assad, though opponents claim such rallies are staged by his regime.
Activists say Soueid's indictment reflects one aspect of a crackdown on the popular revolt in Syria that extends well beyond the country's borders. In June, Britain's Foreign Office summoned Syria's ambassador amid reports that a diplomat had been intimidating Syrian protesters in the UK.
An Amnesty International report issued on Oct. 3 said protesters outside Syria have been systematically monitored and harassed by embassy officials and others believed to be acting on behalf of the Syrian regime.
"The mentality of the Syrian regime is to track all the dissidents and know what they're doing," said Ahed al-Hendi, a Syrian dissident who arrived in the United States as a political refugee and helped coordinate demonstrations in Washington.
Soueid was arrested Tuesday and charged with acting in the U.S. as an unregistered agent of a foreign government, according to an indictment unsealed Wednesday.
According to the indictment, Soueid sent 20 audio and video recordings between April and June to Syria's intelligence agency, the Mukhabarat.
The indictment also states he traveled to Syria in June to meet with Assad personally. He was searched and questioned by authorities upon his return to Washington Dulles International Airport. Soueid informed his handler that he would have to change his procedures in the future as a result of the scrutiny, but that the he would continue his work on the "project."
Prosecutors claim he also tried to recruit others to monitor anti-Assad rallies and protests in the U.S.
A federal magistrate ordered Soueid held Wednesday pending a detention hearing Friday after prosecutor Dennis Fitzpatrick said Soueid represents "a serious risk of flight." He faces up to 40 years in prison if convicted on all six counts.
Soueid, dressed in a black fleece pullover and blue jeans, said he had not yet had a chance to contact his attorney, but did not say who his attorney is. Court records do not list one. Soueid had worked in the past as a manager at an import auto dealership, according to former colleagues.
Soueid was already named as a defendant in a lawsuit filed by anti-Assad activists against multiple government officials, including Assad.
That lawsuit claims that through Soueid's efforts, "the (Assad) regime learns the identities of Syrians based in the United States, who are trying to assist in the efforts to counteract the tactics of the (Assad) regime. He transmits such information to Damascus to initiate criminal conduct against the families of the identified Syrians."
Plaintiffs' lawyer Martin McMahon said one of the plaintiffs had her father murdered by the regime and her home in Syria burned down. After the lawsuit was filed, she said her 5-year-old daughter in Syria was kidnapped, though eventually returned safely.
"Those people over there, they really play rough," McMahon said.
Al-Hendi, the Syrian dissident, is also a plaintiff in the suit. He said protesters at multiple rallies noticed a man who arrived in a Hummer and snapped pictures of the crowd. Demonstrators assumed that pictures were not being taken for innocent purposes, he said.
Syria's embassy in Washington called the allegations "lies and distortions."
"These preposterous allegations claim that the embassy is involved in targeting or intimidating Syrian expatriates in the U.S., which is absolutely untrue," it said in a statement commenting on the Amnesty report.
The U.S. State Department supports the Syrian opposition but says it must diversify its movement to include minorities and show it would improve conditions after Assad. The department had concerns going back to July and August about the Syrian embassy abusing its diplomatic protections and asked the FBI to pursue it.
"The concern remains that we have the Syrian government seeking to intimidate Syrians in the U.S. and Syrian-Americans, and it's unacceptable," department spokeswoman Victoria Nuland said.
Federal prosecutors called the case a threat to American's constitutional freedom to assemble.
"The ability to assemble and protest is a cherished right in the United States, and it's troubling that a U.S. citizen from Leesburg is accused of working with the Syrian government to identify and intimidate those who exercise that right," said U.S. Attorney for the Eastern District of Virginia Neil MacBride, whose office is prosecuting the case.
The White House said the case showed desperation by the Syrian government.
"This desperate effort to monitor protesters in the United States shows that the Assad regime is grasping for any means to silence those speaking out against their brutal crackdown on peaceful protesters," National Security Council spokesman Tommy Vietor said.
___
Associated Press writers Matt Apuzzo and Eric Tucker in Washington, Albert Aji in Damascus and Zeina Karam in Beirut contributed to this report.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_u-ajUnHNNcRM68ef1WNJT1jCnCvN3PRJ95HMwM97dGheHGznKI0JLqKjAfKIUdoz5uhvhtQz7XmxGw_ZNSP1QcewZCH_LHS9_TGe5kdEo=s0-d){kind=small}
Public release date: 14-Oct-2011
Share ]